These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33832113)

  • 41. Pityriasis rosea like eruption: A dermatological manifestation of Coronavac-COVID-19 vaccine.
    Gökçek GE; Öksüm Solak E; Çölgeçen E
    Dermatol Ther; 2022 Feb; 35(2):e15256. PubMed ID: 34881483
    [No Abstract]   [Full Text] [Related]  

  • 42. Interventions for pityriasis rosea.
    Contreras-Ruiz J; Peternel S; Jiménez Gutiérrez C; Culav-Koscak I; Reveiz L; Silbermann-Reynoso ML
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pityriasis rosea in secondary schools in Ouagadougou, Burkina Faso].
    Traore A; Korsaga-Some N; Niamba P; Barro F; Sanou I; Drabo YJ
    Ann Dermatol Venereol; 2001 May; 128(5):605-9. PubMed ID: 11427793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection.
    Paolino G; Di Nicola MR; Cantisani C; Mercuri SR
    Dermatol Ther; 2021 Jul; 34(4):e14972. PubMed ID: 33993616
    [No Abstract]   [Full Text] [Related]  

  • 46. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.
    Avallone G; Quaglino P; Cavallo F; Roccuzzo G; Ribero S; Zalaudek I; Conforti C
    Int J Dermatol; 2022 Oct; 61(10):1187-1204. PubMed ID: 35141881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia.
    Pezzarossa E; Ungari M; Caresana G; Sagradi F; Cimardi L; Pan A; Testa S; Aguggini S; Varotti E; Tanzi G; Manotti L; Ferrero G; Gusolfino MD; Trombatore M;
    Am J Dermatopathol; 2021 May; 43(5):342-348. PubMed ID: 33405402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19-associated pityriasis rosea in children: Case report and literature review.
    Khalili M; Abtahi-Naeini B; Rastegarnasab F; Afshar K
    Clin Case Rep; 2022 Jul; 10(7):e6096. PubMed ID: 35865772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of high-dose acyclovir in pityriasis rosea.
    Drago F; Vecchio F; Rebora A
    J Am Acad Dermatol; 2006 Jan; 54(1):82-5. PubMed ID: 16384760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Negative SARS-CoV-2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea-like eruptions.
    Welsh E; Cardenas-de la Garza JA; Brussolo-Marroquín E; Cuellar-Barboza A; Franco-Marquez R; Ramos-Montañez G
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e661-e662. PubMed ID: 35471706
    [No Abstract]   [Full Text] [Related]  

  • 51. Detection of human herpesvirus 7 in pityriasis rosea by nested PCR.
    Karabulut AA; Koçak M; Yilmaz N; Eksioglu M
    Int J Dermatol; 2002 Sep; 41(9):563-7. PubMed ID: 12358824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea.
    Sonthalia S; Kumar A; Zawar V; Priya A; Yadav P; Srivastava S; Gupta A
    J Dermatolog Treat; 2018 Sep; 29(6):617-622. PubMed ID: 29363373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pityriasis rosea Gibert: detection of Legionella micdadei antibodies in patients.
    Gjenero-Margan I; Vidovic R; Drazenovic V
    Eur J Epidemiol; 1995 Aug; 11(4):459-62. PubMed ID: 8549715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection.
    Drago F; Broccolo F; Ciccarese G; Rebora A; Parodi A
    Dermatology; 2015; 230(1):23-6. PubMed ID: 25612842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comment on 'Negative SARS-CoV-2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea-like eruptions'.
    Ciccarese G; Broccolo F; Parodi A; Drago F
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e37-e38. PubMed ID: 35974703
    [No Abstract]   [Full Text] [Related]  

  • 56. Atypical presentations of pityriasis rosea: case presentations.
    Chuh A; Zawar V; Lee A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):120-6. PubMed ID: 15649208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pityriasis Rosea Induced by COVID-19 Vaccination.
    Khattab E; Christaki E; Pitsios C
    Eur J Case Rep Intern Med; 2022; 9(2):003164. PubMed ID: 35265550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pityriasis rosea: a natural history of pediatric cases in theCentral Anatolia Region of Turkey.
    Çölgeçen E; Kader Ç; Ulaş Y; Öztürk P; Küçük Ö; Balcı M
    Turk J Med Sci; 2016 Dec; 46(6):1740-1742. PubMed ID: 28081320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection.
    Ehsani AH; Nasimi M; Bigdelo Z
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e436-e437. PubMed ID: 32359180
    [No Abstract]   [Full Text] [Related]  

  • 60. [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].
    Erensoy S
    Mikrobiyol Bul; 2020 Jul; 54(3):497-509. PubMed ID: 32755524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.